Comparison
Hexarelin vs Rapamycin
Side-by-side of Hexarelin and Rapamycin. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Hexarelin
Hexarelin peptide is a ghrelin-receptor hexapeptide. Largest acute GH pulse in the GHRP class, highest cortisol and prolactin lift, CD36 cardioprotective sign.
Rapamycin
Rapamycin for longevity: sirolimus, an mTOR inhibitor with ITP mouse lifespan data. Off-label geroprotective dosing remains investigational.
Effects at a glance
Hexarelin
- •Synthetic hexapeptide GHS-R1a agonist; produces the largest acute GH pulse of the synthetic GHRP class
- •Independent CD36 signaling produces cardioprotective effects in rodent ischemia models, GH-independent
- •Pronounced tachyphylaxis: GH response attenuates over 2 to 4 weeks of daily dosing
- •More cortisol and prolactin elevation than GHRP-2 or ipamorelin
- •Anecdotal protocols use 100 to 200 mcg subcutaneously 1 to 2 times daily for 2 to 4 week pulses
- •Banned by WADA under S2; advanced through phase 2 trials but never reached registration
Rapamycin
- •Inhibits mTORC1 signaling by binding FKBP12, reducing protein synthesis and relieving autophagy suppression
- •ITP mouse program reproduced lifespan extension of ~10 to 25% across multiple genetic backgrounds and sexes
- •Mannick trials showed improved influenza vaccine response in elderly adults using analogs of rapamycin
- •PEARL human trial reported acceptable safety at 5 to 10 mg weekly with some functional and lean-mass signals
- •Common dose-limiting adverse effects include stomatitis, acne-like rash, and mildly elevated lipid markers
- •CYP3A4 substrate: grapefruit, ketoconazole, and clarithromycin substantially raise rapamycin exposure
Side-by-side
| Attribute | Hexarelin | Rapamycin |
|---|---|---|
| Category | peptide | pharmaceutical |
| Also known as | Examorelin, EP-23905, His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2 | Sirolimus, Rapamune |
| Half-life (hr) ↗ | 1 | 62 |
| Typical dose (mg) ↗ | 0.1 | 6 |
| Dosing frequency | 1-2x daily | weekly (longevity protocols); daily for transplant indication |
| Routes | subcutaneous, intranasal, intravenous | oral |
| Onset (hr) | 0.25 | 1 |
| Peak (hr) | 0.5 | 2 |
| Molecular weight | 887.04 | 914.17 |
| Molecular formula | C47H58N12O6 | C51H79NO13 |
| Mechanism | Hexapeptide agonist of GHS-R1a producing acute GH release with cortisol and prolactin co-elevation. Independent CD36 binding produces GH-independent cardioprotective signaling in preclinical models. | Binds FKBP12, and the resulting complex inhibits mTORC1, reducing protein synthesis and autophagy suppression downstream of nutrient and growth-factor signaling. |
| Legal status | Not FDA approved; advanced through phase 2 trials in EU but never registered; research-use-only grey market; banned by WADA | Prescription only (off-label for longevity) |
| WADA status | banned | allowed |
| DEA / Rx | Not scheduled (research chemical) | Rx only (not a controlled substance) |
| Pregnancy | Insufficient data; not recommended | Not recommended |
| CAS | 140703-51-1 | 53123-88-9 |
| PubChem CID | 3037387 | 5284616 |
| Wikidata | Q5743550 | Q410174 |
Safety profile
Hexarelin
Common side effects
- water retention
- vivid dreams
- head pressure or flushing
- transient lethargy
- tingling at injection site
- moderate hunger
Contraindications
- pregnancy
- active malignancy
- history of pituitary tumor
- uncontrolled diabetes
- prolactin-sensitive states
Interactions
- CJC-1295: synergistic GH release; accelerates tachyphylaxis if used continuously(minor)
- sermorelin: additive GH release via parallel GHRH and ghrelin pathways(minor)
- insulin: sustained GH can blunt insulin sensitivity over weeks(moderate)
- corticosteroids: amplify cortisol load; blunt GH response(moderate)
Rapamycin
Common side effects
- mouth ulcers (stomatitis)
- acne-like rash
- GI upset
- altered lipid panel
- delayed wound healing
Contraindications
- active infection
- severe hepatic impairment
- planned surgery (delayed wound healing)
- pregnancy
- live vaccines within dosing window
Interactions
- strong CYP3A4 inhibitors (ketoconazole, clarithromycin, grapefruit): substantially raises rapamycin levels, toxicity risk(major)
- strong CYP3A4 inducers (rifampin, St John's wort): lowers rapamycin levels, reduced effect(major)
- ACE inhibitors: increased risk of angioedema(moderate)
- live vaccines: reduced vaccine efficacy due to immunosuppression(major)
Which Should You Take?
Rapamycin comes out ahead for most readers on the criteria we weight: 2 catalogued goals, prescription-only, oral dosing, with a Tier-A outcome catalogued. Hexarelin is the right call when one of the conditionals below applies.
- → If your priority is growth-hormone axis, pick Hexarelin.
- → If your priority is post-training recovery, pick Hexarelin.
- → If your priority is healthspan extension, pick Rapamycin.
- → If your priority is immune support, pick Rapamycin.
Edge case: If you cannot self-administer injections, Rapamycin is the only oral option in this pair.
Default choice: Rapamycin. Wider use case, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for Hexarelin only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Hexarelin and Rapamycin?
Hexarelin and Rapamycin differ in category (peptide vs pharmaceutical), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Hexarelin or Rapamycin?
Hexarelin half-life is 1 hours; Rapamycin half-life is 62 hours.
Can you stack Hexarelin with Rapamycin?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper